Novel adenosine derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective
Mahran, Hanan A.
Ibrahim, Ibrahim M.
Ibrahim, Mohamed N.
Elfiky, Abdo A.
Elshemey, Wael M.
Online Publication Date2021-06-24
Print Publication Date2021-12
Permanent link to this recordhttp://hdl.handle.net/10754/671125
MetadataShow full item record
AbstractBackground: SARS-CoV-2 is a newly emerged human coronavirus that severely affected human health and the economy. The viral RNA-dependent RNA polymerase (RdRp) is a crucial protein target to stop virus replication. The adenosine derivative, remdesivir, was authorized for emergency use 10 months ago by the United States FDA against COVID-19 despite its doubtful efficacy against SARS-CoV-2. Methods: A dozen modifications based on remdesivir are tested against SARS-CoV-2 RdRp using combined molecular docking and dynamics simulation in this work. Results: The results reveal a better binding affinity of 11 modifications compared to remdesivir. Compounds 8, 9, 10, and 11 show the best binding affinities against SARS-CoV-2 RdRp conformations gathered during 100 ns of the Molecular Dynamics Simulation (MDS) run (− 8.13 ± 0.45 kcal/mol, − 8.09 ± 0.67 kcal/mol, − 8.09 ± 0.64 kcal/mol, and − 8.07 ± 0.73 kcal/mol, respectively). Conclusions: The present study suggests these four compounds as potential SARS-CoV-2 RdRp inhibitors, which need to be validated experimentally. Graphic abstract: [Figure not available: see fulltext.]
CitationSonousi, A., Mahran, H. A., Ibrahim, I. M., Ibrahim, M. N., Elfiky, A. A., & Elshemey, W. M. (2021). Novel adenosine derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective. Pharmacological Reports. doi:10.1007/s43440-021-00300-9
SponsorsShaheen supercomputer of King Abdullah University of Science and Technology (KAUST) is used to perform the after dockings MDS calculations (under Project Number k1482). In addition, the Bibliotheca Alexandrina is used to perform the initial MDS calculations. This work is supported by the Cairo University COVID-19 fund received by AAE.
PublisherSpringer Science and Business Media LLC
PubMed Central IDPMC8222949
CollectionsPublications Acknowledging KAUST Support
- Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study.
- Authors: Wakchaure PD, Ghosh S, Ganguly B
- Issue date: 2020 Nov 25
- Theaflavin-3'-O-gallate a Black-tea Constituent Blocked SARS CoV-2 RNA dependant RNA Polymerase Active-site with Better Docking Results than Remdesivir.
- Authors: Banerjee A, Kanwar M, Maiti S
- Issue date: 2021 Oct
- Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase.
- Authors: Zhang L, Zhou R
- Issue date: 2020 Aug 13
- Remdesivir MD Simulations Suggest a More Favourable Binding to SARS-CoV-2 RNA Dependent RNA Polymerase Mutant P323L Than Wild-Type.
- Authors: Mohammad A, Al-Mulla F, Wei DQ, Abubaker J
- Issue date: 2021 Jun 22
- Piece of the puzzle: Remdesivir disassembles the multimeric SARS-CoV-2 RNA-dependent RNA polymerase complex.
- Authors: Olotu FA, Omolabi KF, Soliman MES
- Issue date: 2021 Jun